Secondary thrombotic microangiopathy following lung transplantation: a multicenter European cohort study
Transplant International · 05.08.2026 · 39
DOI: 10.3389/ti.2026.16046 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Transplant International, online erschienen am 05.08.2026. Verfasst von Zsofia Rosselli und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, University Hospital of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Lung Transplantation, Postoperative Complications, Thrombotic Microangiopathies. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Secondary thrombotic microangiopathy (sTMA) is a rare but severe complication after lung transplantation. We performed a multicenter retrospective cohort study including adult lung transplant recipients diagnosed with de novo sTMA between 2010 and 2023 across five European transplant centers. The primary outcome was incidence of sTMA, with secondary outcomes including clinical presentation, treatment strategies, renal outcomes, and survival. Among 3,747 lung transplantations, 49 cases of sTMA were identified, corresponding to an incidence of 1.33%. Median time to diagnosis was 312 days (IQR 93–546), with 53% occurring within the first post-transplant year. All patients presented with acute kidney injury and laboratory signs of hemolysis, neurological complications were observed in 8%. Therapeutic approaches included plasma exchange (46.9%), anti-C5 therapy (24.5%), and sequential plasma exchange followed by complement inhibition (10.2%). At follow-up, 65.3% developed chronic kidney disease, 20.4% progressed to end-stage renal disease, and 10.2% died during the acute episode. No significant association between treatment modality and renal or survival outcomes was observed. sTMA after lung transplantation is infrequent but associated with substantial renal morbidity and mortality. Early recognition through assessment of hemolysis and kidney injury, supported by renal biopsy in selected cases, may facilitate timely diagnosis and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
- Lung Transplant Program, Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czechia.
- Lung Transplant Program, Department of Pulmonology Hospital Universitari Vall Hebron, Barcelona, Spain.
- Pneumologie et Transplantation Pulmonaire, UCL Namur University Hospital | Godinne Site, Namur, Belgium.
- Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria.
- Department of Pathology, Medical University Vienna, Vienna, Austria.
Zitieren
APA
Rosselli, Z., Havlin, J., Saez-Gimenez, B., Carlier, F. M., Muraközy, G., Jaksch, P., Schwarz, S., Damm, D., Schuurmans, M., Kozakowski, N., Gaggl, M., Schmidt, A., Sunder-Plassmann, G., & Aigner, C. (2026). Secondary thrombotic microangiopathy following lung transplantation: a multicenter European cohort study. Transplant International, 39. https://doi.org/10.3389/ti.2026.16046
Vancouver
Rosselli Z, Havlin J, Saez-Gimenez B, Carlier FM, Muraközy G, Jaksch P, et al. Secondary thrombotic microangiopathy following lung transplantation: a multicenter European cohort study. Transplant International. 2026;39. doi:10.3389/ti.2026.16046
BibTeX
@article{Rosselli2026,
author = {Rosselli, Zsofia and Havlin, Jan and Saez-Gimenez, Berta and Carlier, François M and Muraközy, Gabriella and Jaksch, Peter and Schwarz, Stefan and Damm, Dominik and Schuurmans, Mace and Kozakowski, Nicolas and Gaggl, Martina and Schmidt, Alice and Sunder-Plassmann, Gere and Aigner, Christof},
title = {Secondary thrombotic microangiopathy following lung transplantation: a multicenter European cohort study},
journal = {Transplant International},
year = {2026},
volume = {39},
doi = {10.3389/ti.2026.16046}
}
EUVIMED